Quarterly report [Sections 13 or 15(d)]

NON CONTROLLING INTEREST (Tables)

NON CONTROLLING INTEREST (Tables)

6 Months Ended

Jun. 30, 2025

ROYALTY OBLIGATIONS NET

Schedule of net loss attributable to non-controlling interest

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss		$	(594,446	)		$	(5	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest		$	(143,856	)		$	(2	)

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss		$	(67,251	)		$	(1,072	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest		$	(16,275	)		$	(375	)

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss		$	(637,230	)		$	(15	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest		$	(154,210	)		$	(5	)

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss		$	(68,800	)		$	(1,964	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest		$	(16,650	)		$	(687	)

Schedule of changes in non-controlling interest

Balance, December 31, 2024		$	(234,812	)
Net loss attributable to the non-controlling interest			(154,215	)
Balance, June 30, 2025			(389,027	)

Balance, December 31, 2023		$	(128,834	)
Net loss attributable to the non-controlling interest			(17,337	)
Balance, June 30, 2024			(146,171	)